Dry eye condition is a common pathology affecting around 20 per cent of the Australian population and mainly caused by Meibomian Gland Dysfunction (MGD). The excessive use of smartphones, artificial lights and air pollution can exacerbate the problem.
Over the last three years, E-Eye has proven its efficiency by offering long-lasting relief to more than 35,000 dry eye sufferers. E-Eye is the first and still only IRPL (Intense Regulated Pulsed Light) device specifically developed for the treatment of MGD. The light emitted during the treatment targets the nerve linked to the Meibomian Glands to stimulate them so they can return to their normal function. The treatment is gentle, quick and significant; improvement is experienced after just three sessions in more than 86 per cent of patients. More than treating dry eyes, E-Eye also helps to prevent the disease and treat it at a very early stage.
Contact: France Medical (AUS) 07 3393 9342
